Mercados españoles cerrados

Biogen Inc. (BIIB)

NasdaqGS - NasdaqGS Precio en tiempo real. Divisa en USD
Añadir a la lista de favoritos
349,16-22,74 (-6,11%)
Al cierre: 4:00PM EDT
349,20 0,04 (0,01 %)
Después del cierre: 05:21PM EDT
Inicia sesión para publicar un mensaje.
  • O
    O-Behave
    $BIIB conversation
    $LLY news is GREAT news for $BIIB not bad news. The smoke will clear and we will be heading right back to the $400s

    Hedgefunds are loading here. I guarantee it.

    $BIIB: Cowen Upgrades To Outperform PT $450

    Atlantic Equities Upgrades to Neutral - PT $415

    Citigroup Upgrades to Neutral PT $440

    Oppenheimer Raises Target Price To $450 From $325

    Morgan Stanley Raises Target Price To $455 From $343

    Jeffries PT $500

    SEE U AT $600+💸✈📚📈📽
  • O
    O-Behave
    $BIIB conversation
    BIIB who gave away their shares??! LMFAOOOOO! $LLY just got a fast track designation this has NOTHING on $BIIB. I'm loading these gifts 🎁
  • W
    WealthMastersClub1
    $BIVI conversation
    BioVie Announces Closing of Acquisition of BioPharma Assets from Privately Held NeurMedix
    BioVie, Inc.
    Fri, June 11, 2021, 5:00 AM·2 min read

    BIVI
    +16.61%
    Company Expects to Commence Enrollment in Pivotal Phase 3 Alzheimer’s Trial in Mid-2021

    SANTA MONICA, Calif., June 11, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company") today announced the closing of its previously announced acquisition of the biopharmaceutical assets of NeurMedix, Inc., a privately held clinical-stage pharmaceutical company. The acquired assets include NE3107, a selective inhibitor of inflammatory ERK signaling that reduces neuroinflammation. It is an orally administered first-in-class small molecule that inhibits inflammation-driven insulin resistance and major pathological inflammatory cascades with a novel mechanism of action. There is emerging scientific consensus that both inflammation and insulin resistance play fundamental roles in the development of Alzheimer’s and Parkinson’s Disease, and NE3107 could represent an entirely new medical approach to treating these devastating conditions affecting an estimated 6 million Americans suffering from Alzheimer’s and 1 million from Parkinson’s. The FDA recently authorized a pivotal US Phase 3 clinical trial for NE3107.
    $AVXL $SAVA $ANVS $BIIB
  • W
    WealthMastersClub1
    $BIVI conversation
    BioVie Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®on the Bloomberg Network in the U.S. on this coming Saturday, June 19th, at 7 p.m. local time $ANVS $SAVA $AVXL $BIIB

    To view the interview segment, please visit: https://youtu.be/B9u4xqdT6lc
  • W
    WealthMastersClub1
    $BIVI conversation
    BIVI = Higher ROI
    Company Expects to Commence Enrollment in Pivotal Phase 3 Alzheimer’s Trial in Mid-2021
    $BIIB $ANVS $SAVA $AVXL
  • T
    Tom
    How important is FDA approval?

    $BIIB jumped 60% at one point today, from $268 to about $430 (estimates, numbers not in front of me) on FDA approval for a new Alzheimer’s drug.

    FDA approval means EVERYTHING! When (🤞🏼🤞🏼) this 180-day receives FDA approval in the Fall we can expect the same reaction.
  • t
    thirdmeinvestor
    $VRTX conversation
    June is a very important month for $VRTX, $BIIB, and all biotechs. JPM's Kasimov's thoughts are here:
    https://finance.yahoo.com/news/fate-biogen-stock-rides-fda-124236090.html
  • G
    G money cricket
    $BIIB conversation
    congrats BIIB hodlers! If you are looking for other stocks that will rise with $BIIB today, look no further than $ARFXF... they've been pre-Phase I for a while, pending aducanumab approval. Boston sports magnate billionaires from BIIB's neighborhood recently put $7M into $ARFXF. Their PMN310 is basically the next-gen aducanumab with better binding affinity and selectivity, so it can be dosed higher without causing ARIA-E effects that limit dosing of aducanumab. promis neurosciences is the company name. and the market cap is about 1000X smaller than BIIB, so do the math on that...
  • M
    MikeGamechanger
    Today the FDA approved Aduhelm to treat patients with Alzheimer’s disease using the Accelerated Approval pathway -- this approval is significant in many ways. Aduhelm is the first novel therapy approved for Alzheimer’s disease since 2003 $BIIB #Alzheimers
  • O
    O-Behave
    $BIIB conversation
    $BIIB $407 with day high $410

    $425 next then $440-445 upside
  • O
    O-Behave
    $BIIB conversation
    $BIIB HUGE ARTICLE OUT. Still not seen. The drug WORKS!! No wonder those MASSIVE institutional call sweep buys just kept flying in. See you at $600, the fear mongering myth by the shorts which imply that the drug doesn't work couldn't even last 24 hours lmao! See you at $600+
  • O
    O-Behave
    $BIIB conversation
    $BIIB was the target of unusually large options trading on Monday. Stock investors acquired 111,622 call options on the stock. This is an increase of 1,410% compared to the typical daily volume of 7,392 call options. HUGE MONEY about to pour in to move those call opinions of theirs. TRUST ME. Just math
  • O
    O-Behave
    $BIIB conversation
    $BIIB It’s the FIRST drug cleared by U.S. regulators to slow cognitive decline in people living with Alzheimer’s and the first new medicine for the disease in nearly two decades.
  • O
    O-Behave
    $BIIB conversation
    $BIIB bouncing afterhours! The ONLY drug ever approved for AD. $600+ by end of July? Likely imo.
  • O
    O-Behave
    $BIIB conversation
    Huge SWEEPS rolling in. 500 $BIIB 06/11/21 $395 calls for $8.90

    Spot: $388.17
    Volume/OI: 1901/82
    Premium: $445.0k

    INSTITUTIONS LOADING

    #FACTS #REALITY #NUMBERSDONTLIE

    https://twitter.com/SelectOptions/status/1402302235644620800?s=19
  • O
    O-Behave
    $BIIB conversation
    $BIIB search trends increased by NINE THOUSAND PERCENT today. Whales 🐋🐳💦 coming soon!💸
    https://twitter.com/quantrinsic/status/1402043094623653892?s=19
  • O
    O-Behave
    $BIIB conversation
    I wouldn't be surprised to see $BIIB at $1000 by the end of the year
  • O
    O-Behave
    $BIIB conversation
    Poor $BIIB shorts, the only bash they have has expired. NUMEROUS articles now out of patients confirming that it WORKS. You shorts need to find a new bash. But you can't because even if $BIIB dropped the price to $30,000 per year they still will bring in $150 BILLION! Why do you think it's been trading so STRONG since the articles started hitting the wires? See you at $600+
  • O
    O-Behave
    $BIIB conversation
    $BIIB will be above $450 by Friday EASY. I'm loving the huge block BUYS
  • R
    RV
    $AVXL conversation
    What will FDA do?
    The financial toxicity aspect of $BIIB Aduhelm may be the worst part

    False emotional hope is OK, but what if family finances get drained when insurance doesn’t pay for it all?